Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | AHR | P35869 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502300 | 0.84 | RAB9A (0.76) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL26551637 | 0.78 | APP (0.51) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL20656278 | 0.76 | CDC7 (0.43) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL22761274 | 0.75 | SMN1; SMN2 (0.44) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL6993101 | 0.74 | NPY5R (0.84) | RAB9ANPC1 | |
| SCHEMBL26547901 | 0.74 | ROCK2 (0.46) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL30572262 | 0.74 | CCNE2 (0.48) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL24867160 | 0.73 | NPY5R (0.67) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL6992705 | 0.73 | NPY5R (0.67) | RAB9ANPC1NR1I2AHRSMN1; SMN2 | |
| SCHEMBL4407128 | 0.72 | PIK3C3 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751133-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-04-14 | — | — | EP | disclosed |
| US-7531556-B2 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1751133-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060019956-A1 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| WO-2005105780-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019956-A1 | Compositions useful as inhibitors of rock and other protein kinases | ROCK1, ROCK2, PRKCH | RAB9A 868/4885NPC1 1991/4885NR1I2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.